GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Komipharm International Co Ltd (XKRX:041960) » Definitions » Research & Development

Komipharm International Co (XKRX:041960) Research & Development : ₩3,234 Mil (TTM As of Sep. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Komipharm International Co Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Komipharm International Co's Research & Development for the three months ended in Sep. 2024 was ₩363 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 was ₩3,234 Mil.


Komipharm International Co Research & Development Historical Data

The historical data trend for Komipharm International Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Komipharm International Co Research & Development Chart

Komipharm International Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,649.00 3,265.65 5,117.41 2,535.79 5,944.99

Komipharm International Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 552.38 1,197.38 378.03 1,295.54 363.05

Komipharm International Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩3,234 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Komipharm International Co  (XKRX:041960) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Komipharm International Co Research & Development Related Terms

Thank you for viewing the detailed overview of Komipharm International Co's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Komipharm International Co Business Description

Traded in Other Exchanges
N/A
Address
1236-6 Jungwang-Dong, Sihung, Gyeonggi, KOR, 429-450
Komipharm International Co Ltd is involved in the healthcare sector based in Korea. Its core business includes development and manufacture of veterinary vaccines and veterinary pharmaceuticals. The company produces its products under two divisions: veterinary vaccines such as total vaccines of respiratory disease for swine, vaccines of anthrax disease and black leg for cattle. The other division is made up of veterinary pharmaceuticals such as antibiotics, nutrients, disinfectants and others, which are used to treat pneumonia, pasteurellosis, enteritis, mastitis and swine erysipelas.

Komipharm International Co Headlines

No Headlines